OOIR: Observatory of International Research

Papers

(The TQCC of Diabetes & Metabolism is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Metformin and COVID-19: From cellular mechanisms to reduced mortality	140
Body mass index and outcome in patients with COVID-19: A dose–response meta-analysis	104
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment	100
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials	86
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients	85
Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes	74
A systematic review of nudge theories and strategies used to influence adult health behaviour and outcome in diabetes management	66
Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes	65
Cardiovascular disease in type 1 diabetes: A review of epidemiological data and underlying mechanisms	63
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19	58
Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study	56
Effects of COVID-19 pandemic lockdown on gestational diabetes mellitus: A retrospective study	55
Elevated triglyceride–glucose index predicts risk of incident ischaemic stroke: The Rural Chinese cohort study	48
Meat and fish intake and type 2 diabetes: Dose–response meta-analysis of prospective cohort studies	47
Smoking and diabetes interplay: A comprehensive review and joint statement	47
Triglyceride–glucose index associates with incident heart failure: A cohort study	45
Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19	40
Is the type 2 diabetes epidemic plateauing in France? A nationwide population-based study	35
Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the “Gordian Knot”?	34
Fulminant type 1 diabetes after COVID-19 vaccination	33
Diabetes mellitus in the era of climate change	33
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations	31
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies	31
Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction	29
Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes	29

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19	28
The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies	26
Targeting ageing and preventing organ degeneration with metformin	26
Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease	26
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement	25
Diabetic ketoacidosis and mortality in COVID-19 infection	25
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Dia	24
The obesity treatment dilemma: Why dieting is both the answer and the problem? A mechanistic overview	24
Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes	23
Eye disorders other than diabetic retinopathy in patients with diabetes	23
Practical implementation of automated closed-loop insulin delivery: A French position statement	23
Exposure to persistent organic pollutants and the risk of type 2 diabetes: a case-cohort study	23
Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors	22
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?	21
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study	21
Cardiovascular risks of periodontitis and oral hygiene indicators in patients with diabetes mellitus	21
Lower trabecular bone score in type 2 diabetes mellitus: A role for fat mass and insulin resistance beyond hyperglycaemia	20
Gestational diabetes is associated with SARS-CoV-2 infection during pregnancy: A case-control study	20
SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement	20
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection	19
COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes	19
Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?	19
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?	19
The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients	19
Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: A cohort study of 85,609 pregnant women	19
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes	19
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists	18
Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial	18
Predictors of type 2 diabetes relapse after Roux-en-Y Gastric Bypass: A ten-year follow-up study	18
Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan	17
Three alternative ways to screen for hyperglycaemia in pregnancy during the COVID-19 pandemic	16
Determinants of aspirin resistance in patients with type 2 diabetes	16
Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study	16
Sodium–glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells	16
Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study	16
Associations of serum magnesium levels and calcium–magnesium ratios with mortality in patients with coronary artery disease	16
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectI	15
Association of hyperglycaemia with hospital mortality in nondiabetic COVID-19 patients: A cohort study	15
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis	15
A high lean body mass is not protecting from type 2 diabetes in the presence of a high body fat mass	15
Association between sleep duration in early pregnancy and risk of gestational diabetes mellitus: a prospective cohort study	15
Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study	15
Euglycaemic ketoacidosis during gestational diabetes with concomitant COVID-19 infection	15
Steatotic liver disease, MASLD and risk of chronic kidney disease	14
Liraglutide 3 mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma	14
Concise review of lipidomics in nonalcoholic fatty liver disease	14
Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort	14
Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function	14
Prevalence and risk of diabetic complications in young-onset versus late-onset type 2 diabetes mellitus	14
Impact of gender on relative rates of cardiovascular events in patients with diabetes	13

Bidirectional relationship between diabetes and pulmonary function: a systematic review and meta-analysis	13
Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers	13
Glycaemic control for painful diabetic peripheral neuropathy is more than fasting plasma glucose and glycated haemoglobin	13
Dose–response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease	12
Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes	12
Type 1 diabetes mellitus and risks of major psychiatric disorders: A nationwide population-based cohort study	12
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?	12
Dietary sodium and potassium and risk of diabetes: A prospective study using data from the China Health and Nutrition Survey	12
Metabolic characteristics and adverse pregnancy outcomes for women with hyperglycaemia in pregnancy as a function of insulin resistance	11
Glycaemic variabilities: Key questions in pursuit of clarity	11
Distinct uric acid trajectories are associated with incident diabetes in an overweight Chinese population	11
Objective and subjective sleep measures are associated with HbA1c and insulin sensitivity in the general population: Findings from the ORISCAV-LUX-2 study	11
Prognosis associated with initial care of increased fasting glucose in early pregnancy: A retrospective study	11
SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus	11